Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

May 21, 2019

SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase inhibitor, in adult patients with progressing desmoid tumors.

SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors